Vismed (sodium hyaluronate) / TRB Chemedica - LARVOL DELTA

Real-World Performance and Safety of VISIOL in Modern Routine Cataract Surgery. (PubMed, Ophthalmol Ther) - P | "In patients with severe cataracts, including those with glaucoma, VISIOL demonstrated excellent safety, minimal complications, and favourable surgical outcomes."

Journal • Real-world evidence • Cataract • Glaucoma • Inflammation • Ophthalmology

Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Medivis SRL

New trial • Conjunctivitis • Dry Eye Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome

Performance and Safety of T2769 in DED (clinicaltrials.gov) - P=N/A | N=251 | Completed | Sponsor: Laboratoires Thea | Recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Shear-Stress-Dependent Viscous Properties of Hyaluronic-Based Lubricants. (PubMed, J Clin Med) - " This study demonstrates that commercially available ocular lubricants exhibit varying degrees of shear-thinning behavior, a finding that is clinically relevant for their performance on the ocular surface. Formulations containing low-molecular-weight hyaluronic acid, such as Thealoz® Duo, exhibited viscosity values closest to those of natural tears at the measured shear rates."

Journal • Dry Eye Disease • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: Santen SAS | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Sep 2026 | Trial primary completion date: Dec 2024 ➔ Sep 2026

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=83 | Completed | Sponsor: Santen SAS | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Apr 2025 | Trial primary completion date: Dec 2024 ➔ Apr 2025

Head-to-Head • Trial completion • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Vaccines Assessment: different approaches on serological assays (WVCE 2024) - "Sponsored by: Vismederi"

Overview of 37 Tear Substitutes in Europe Based on Various Physicochemical Parameters. (PubMed, Ophthalmol Ther) - "While the perfect eye drop does not exist, a multitude of options are available to choose from. This study improves our understanding of the major tear substitutes available on the European market based on several physicochemical properties. A better understanding and awareness of these parameters is crucial in order to offer the best treatment for patients with DED."

Journal • Dry Eye Disease • Ophthalmology

A randomised study comparing performance and safety of Eyestil Plus® vs Vismed Multi® in moderate-to-severe dry eye syndrome patients. (PubMed, Eur J Ophthalmol) - "This clinical investigation showed the non-inferiority of Eyestil Plus® compared to Vismed Multi® regarding performance and safety in a moderate-to-severe DED population."

Journal • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Sjogren's Syndrome

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome (clinicaltrials.gov) - P=N/A | N=226 | Recruiting | Sponsor: Laboratoires Thea | Not yet recruiting ➔ Recruiting

Enrollment open • Dry Eye Disease • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Oct 2023 ➔ Dec 2024 | Trial primary completion date: Oct 2023 ➔ Dec 2024

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome (clinicaltrials.gov) - P=N/A | N=226 | Not yet recruiting | Sponsor: Laboratoires Thea

New trial • Dry Eye Disease • Ophthalmology

Randomized Clinical Trial of Topical Insulin Versus Artificial Tears for Healing Rates of Iatrogenic Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. (PubMed, Cornea) - "Topical insulin (0.5 units, 4 times per day) is more effective compared with artificial tears (Vismed, sodium hyaluronate 0.18%, 4 times per day) for the healing of postoperative corneal epithelial defects induced during vitreoretinal surgery in diabetic patients, without any adverse events."

Clinical • Journal • Surgery • Diabetes • Metabolic Disorders

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Feb 2023 ➔ Oct 2023 | Trial primary completion date: Oct 2022 ➔ Oct 2023

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Apr 2023 ➔ Dec 2023

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

"@Microbiologics @newsfrom_MP @Merck @Microbiologics @naobios @OsivaxVaccines @PrecisionNano @sanofi @serimmune @SibrosTech @Studykik @TouchlightDNA @utmbhealth @Vaxart @Vaxess @VBIVaccines @vernalbio @VisMederi" (@vaccinenation)

Clinical

Idroflog® for Treatment of Dry Eye Disease (IDROFLOG) (clinicaltrials.gov) - P=N/A | N=130 | Not yet recruiting | Sponsor: Alfa Intes Industria Terapeutica Splendore s.r.l.

New trial • Dry Eye Disease • Ophthalmology

A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® (clinicaltrials.gov) - P=N/A | N=96 | Completed | Sponsor: SIFI SpA | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • Dry Eye Disease • Ocular Inflammation • Ophthalmology

"@vismed3D @WomenInMedicine @womenandmed @ptkirchgraber @UChicago @UWMedicine @PennMedicine @UofIllinois @NorthShoreWeb @WeinbergCollege @NorthwesternU @RushMedical @avolgman @DoctorADDA @BrownMedAMWA @IUSMDeptMed @RFUniversity @SmartHealth_NUS @IUVentures @IUWellsCenter" (@dimaelissa)

Clinical

"@VaxtrialsO @VisMederi @UKHSA @Tofflon @SEPPIC @Roche @PallCorporation @novotechCRO @Microbiologics @MeridianClinRes @LeukocareAG @JuliusClinical @IVIHeadquarters @CleanCells @BIOASTER @Asphalion @Allucent_CRO @ACROBio @3PBio @Mabtech @CEVAXIN_PTY @provepharm" (@vaccinenation)

PROSIKA: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2022 ➔ Feb 2023 | Trial primary completion date: Apr 2022 ➔ Oct 2022

Enrollment open • Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

ALHENA: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (clinicaltrials.gov) - P=N/A | N=80 | Recruiting | Sponsor: Santen SAS | Trial completion date: Dec 2022 ➔ Jul 2023 | Trial primary completion date: Jul 2022 ➔ Apr 2023

Head-to-Head • Trial completion date • Trial primary completion date • Conjunctivitis • Dry Eye Disease • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology

To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance (clinicaltrials.gov) - P=N/A | N=21 | Terminated | Sponsor: SIFI SpA | SIFI has developed a new product with probably a better performance. SIFI changed its marketing strategy and decided that Eyestil® Protection will be not marketed anymore

Enrollment change • Head-to-Head • Trial termination • Dry Eye Disease • Ocular Inflammation • Ophthalmology

A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: SIFI SpA | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2021 ➔ Aug 2022 | Trial primary completion date: Dec 2021 ➔ May 2022

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Dry Eye Disease • Ocular Inflammation • Ophthalmology